Elutia (ELUT) Expected to Post Quarterly Earnings on Thursday

Elutia (NASDAQ:ELUT) is projected to announce its Q3 2026 results after the market closes on Thursday, November 5th. Analysts expect Elutia to announce earnings of ($0.15) per share and revenue of $1.00 million for the quarter. Individuals can check the company’s upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Thursday, November 5, 2026 at 5:00 PM ET.

Elutia (NASDAQ:ELUT) last released its quarterly earnings data on Thursday, August 13th. The company reported ($0.17) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.15) by ($0.02). Elutia had a negative return on equity of 407.37% and a net margin of 426.93%. The business had revenue of $2.43 million for the quarter, compared to analyst estimates of $2.90 million.

Elutia Stock Down 0.4%

ELUT traded down $0.00 on Wednesday, reaching $0.81. The company had a trading volume of 17,335 shares, compared to its average volume of 163,843. Elutia has a 1 year low of $0.50 and a 1 year high of $1.39. The stock has a market capitalization of $35.87 million, a PE ratio of 0.85 and a beta of 0.93. The stock has a 50-day moving average price of $0.83 and a 200-day moving average price of $0.97.

Wall Street Analyst Weigh In

Separately, Weiss Ratings downgraded Elutia from a “sell (d)” rating to a “sell (e+)” rating in a research note on Thursday, October 8th. One investment analyst has rated the stock with a Sell rating. According to MarketBeat.com, the stock currently has an average rating of “Sell”.

About Elutia

Elutia Inc is a medical technology company focused on developing and commercializing biologic products designed to support tissue healing and improve the performance of implantable medical devices. The company combines human tissue-based materials with drug-delivery and regenerative medicine technologies.

Its product portfolio includes biologic envelopes used to protect and support cardiac implantable electronic devices, including pacemakers and defibrillators. Elutia also develops tissue matrices and other biologic products for orthopedic, wound care and related surgical applications, with products intended to support soft-tissue repair, reconstruction and healing.

The company was formerly known as Aziyo Biologics and adopted the Elutia name as part of its broader focus on bioelectronic medicine and regenerative healthcare.